We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The significance of secukinumab in the treatment of plaque psoriasis.
- Authors
Kasprowicz-Furmańczyk, Marta; Owczarczyk-Saczonek, Agnieszka
- Abstract
Psoriasis is a chronic inflammatory skin disease that affects approximately 1-3% of the general population in Poland. It is estimated that in 70-80% of patients skin lesions are mild and require only topical medications. In severe plaque psoriasis, classic treatments often lead to a loss of efficacy, adverse effects or insufficient treatment effect, therefore it is necessary to search for new therapeutic methods. Multiple studies show that secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), has significant efficacy in the treatment of moderate to severe psoriasis, demonstrating a rapid onset of action and sustained response with a good safety profile. The role of secukinumab in the treatment of plaque psoriasis is discussed in this article.
- Subjects
POLAND; PSORIASIS treatment; INTERLEUKIN-17; MONOCLONAL antibodies; DRUG side effects
- Publication
Dermatology Review / Przeglad Dermatologiczny, 2021, Vol 108, Issue 5, p372
- ISSN
0033-2526
- Publication type
Article
- DOI
10.5114/dr.2021.113155